John A Katzenellenbogen
Overview
Explore the profile of John A Katzenellenbogen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
280
Citations
6898
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rej R, Hu B, Chen Z, Acharyya R, Wu D, Metwally H, et al.
J Med Chem
. 2024 Nov;
67(23):20933-20965.
PMID: 39585895
Inhibition of estrogen receptor alpha (ERα) signaling is an established therapeutic approach for the treatment of ER-positive (ER+) breast cancers, but new therapeutic strategies are urgently needed to overcome clinical...
2.
Angle S, Sharma H, Choi C, Carlson K, Hou Y, Nwachukwu J, et al.
J Am Chem Soc
. 2024 Oct;
146(45):30771-30777.
PMID: 39481083
We report the development of an iterative Matteson homologation reaction with catalyst-controlled diastereoselectivity through the design of a new catalyst. This reaction was applied to the selective synthesis of each...
3.
Kumar S, Ziegler Y, Plotner B, Flatt K, Kim S, Katzenellenbogen J, et al.
Breast Cancer Res Treat
. 2024 Jul;
208(2):307-320.
PMID: 38980505
Purpose: Cancer treatments often become ineffective because of acquired drug resistance. To characterize changes in breast cancer cells accompanying development of resistance to inhibitors of the oncogenic transcription factor, FOXM1,...
4.
Min C, Nwachukwu J, Hou Y, Russo R, Papa A, Min J, et al.
Proc Natl Acad Sci U S A
. 2024 Jun;
121(24):e2321344121.
PMID: 38830107
The estrogen receptor-α (ER) is thought to function only as a homodimer but responds to a variety of environmental, metazoan, and therapeutic estrogens at subsaturating doses, supporting binding mixtures of...
5.
Liu C, Vorderbruggen M, Munoz-Trujillo C, Kim S, Katzenellenbogen J, Katzenellenbogen B, et al.
J Ovarian Res
. 2024 May;
17(1):94.
PMID: 38704607
Background: Genetic studies implicate the oncogenic transcription factor Forkhead Box M1 (FOXM1) as a potential therapeutic target in high-grade serous ovarian cancer (HGSOC). We evaluated the activity of different FOXM1...
6.
Min C, Nwachukwu J, Hou Y, Russo R, Papa A, Min J, et al.
bioRxiv
. 2024 Apr;
PMID: 38645081
Significance: The estrogen receptor-α (ER) regulates transcription in response to a hormonal milieu that includes low levels of estradiol, a variety of environmental estrogens, as well as ER antagonists such...
7.
Febrissy C, Adlanmerini M, Pequeux C, Boudou F, Buscato M, Gargaros A, et al.
Theranostics
. 2024 Jan;
14(1):249-264.
PMID: 38164151
: 17β-estradiol (E2) can directly promote the growth of ERα-negative cancer cells through activation of endothelial ERα in the tumor microenvironment, thereby increasing a normalized tumor angiogenesis. ERα acts as...
8.
Kingston B, Pearson A, Herrera-Abreu M, Sim L, Cutts R, Shah H, et al.
Cancer Discov
. 2023 Nov;
14(2):274-289.
PMID: 37982575
Significance: Novel F404 ESR1 mutations may be acquired to cause overt resistance to fulvestrant when combined with preexisting activating ESR1 mutations. Novel combinations of mutations in the ER ligand binding...
9.
Irani S, Tan W, Li Q, Toy W, Jones C, Gadiya M, et al.
J Clin Invest
. 2023 Oct;
134(1).
PMID: 37883178
Physiologic activation of estrogen receptor α (ERα) is mediated by estradiol (E2) binding in the ligand-binding pocket of the receptor, repositioning helix 12 (H12) to facilitate binding of coactivator proteins...
10.
Sacharidou A, Chambliss K, Peng J, Barrera J, Tanigaki K, Luby-Phelps K, et al.
Nat Commun
. 2023 Aug;
14(1):4989.
PMID: 37591837
The estrogen receptor (ER) designated ERα has actions in many cell and tissue types that impact glucose homeostasis. It is unknown if these include mechanisms in endothelial cells, which have...